All the Drug Class Drugs
Anti HIV, Antivirals for Treatment of HIV Infections, Antivirals/HIV, Non-Nucleoside Reverse Transcriptase Inhibitors. Rilpivirine 600 mg, 900 mg. susp. for IM. inj. Prol.Rel. 2/3 ml
One 900 mg injection /mo followed by a 600 mg inj. on the next mo. Treat. may be preceded by oral rilpirivine tabs. (lead-in ther.) to assess tolerability. See full prescr. details.
In combin. with cabotegravir inject., for tmt. of human immunodefic. virus type 1 (HIV-1) infect. in adlts. who are virolog. suppress. (HIV-1 RNA < 50 copies/mL) on a stable antiretrov. regim. w/o pres. or past evid. of viral resist. to, and no prior virolog. failure with, agents of the NNRTI and INI class.
C/I: Hypersens. Co-admin. with the follow. med. products:
-anticonvuls.: carbamazepine, oxcarbazepine, phenobarbital, phenytoin,
-antimycobact.: rifabutin, rifampicin, rifapentine,
-syst. glucocorticoid dexamethasone, except as a sgle. dose tmt.,
-St. John’s wort (Hypericum perforatum).
Antivirals/HIV. Cabotegravir 200 mg/ml. Prolonged-release suspension for injection 400 mg/ 2 ml, 600 mg/3 ml
Initiation injection (600 mg) On the final day of current antiretroviral ther. or oral lead-in ther.,single 600 mg by IM inject. Rilpivirine inject. should be admin. at separate gluteal site at the same visit.
Continuation injection (400 mg) single 400 mg monthly by IM inject. Rilpivirine inject. should be admin. at separate gluteal site at the same visit. Pts may be given inject. up to 7 days before or after the date of the monthly 400 mg injection sched.
In combin. with rilpivirine injection, for the tmt.of HIV-1 infect. in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resist. to, and no prior virological fail. with agents of the NNRTI and INI class.
C/I: Concom. use with rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or phenobarbital. Hypersens.
